Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19316708 | SELF-REGULATING PHOTO-CURABLE COOLING HYDROGEL AND PREPARATION METHOD AND APPLICATION THEREOF | September 2025 | January 2026 | Allow | 4 | 0 | 1 | Yes | No |
| 18979844 | LOW SODIUM OXYBATE ONCE NIGHTLY COMPOSITION | December 2024 | September 2025 | Allow | 9 | 1 | 1 | No | No |
| 18926566 | COENZYME Q10 COMPOSITION, AND PREPARATION METHOD AND APPLICATION THEREOF IN CARDIO-PROTECTION | October 2024 | January 2025 | Allow | 3 | 0 | 0 | No | No |
| 18700209 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | April 2024 | April 2025 | Allow | 12 | 0 | 0 | Yes | No |
| 18581968 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | February 2024 | July 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18438349 | Compositions Comprising Antioxidant, Fluid Dispensers, and Methods Involving the Same | February 2024 | November 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18409041 | MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | January 2024 | September 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18541083 | INJECTABLE FORMULATION | December 2023 | February 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18538991 | COMPOSITIONS FOR ORAL MUCOADHESIVE DOSAGE FORMS | December 2023 | May 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18389206 | CONTROLLED DRUG RELEASE FORMULATION | November 2023 | September 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18505414 | Low-Dose Stable Formulations of Linaclotide | November 2023 | June 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18386522 | INTRACAMERAL IMPLANT FOR TREATMENT OF AN OCULAR CONDITION | November 2023 | May 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18468542 | METHOD FOR MORSELIZING AND/OR TARGETING PHARMACEUTICALLY ACTIVE PRINCIPLES TO SYNOVIAL TISSUE | September 2023 | October 2025 | Allow | 25 | 3 | 1 | No | No |
| 18467916 | DRUG FORMULATIONS COMPRISING POLYOXAZOLINES AS MATRIX EXCIPIENT | September 2023 | November 2024 | Allow | 14 | 1 | 0 | No | No |
| 18244351 | Multi-Layered Graft for Tissue Engineering Applications | September 2023 | November 2025 | Allow | 26 | 1 | 1 | No | No |
| 18236109 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | August 2023 | June 2025 | Allow | 22 | 2 | 0 | Yes | Yes |
| 18233143 | Methods and Devices for Conduit Occlusion | August 2023 | May 2025 | Abandon | 21 | 2 | 0 | No | No |
| 18224560 | RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | July 2023 | June 2024 | Allow | 11 | 2 | 0 | No | No |
| 18219246 | TIME-DEPENDENT SYNTHETIC BIOLOGICAL BARRIER MATERIAL | July 2023 | February 2026 | Allow | 31 | 3 | 1 | No | No |
| 18334408 | THYROID HORMONE ORAL DOSAGE FORMS AND METHODS OF USING THE SAME | June 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18204475 | READY-TO-USE PHARMACEUTICAL COMPOSITIONS OF POTASSIUM PHOSPHATES INJECTION | June 2023 | May 2025 | Abandon | 24 | 3 | 0 | Yes | No |
| 18310607 | ALGINATE HYDROGEL COMPOSITIONS | May 2023 | February 2025 | Allow | 22 | 1 | 1 | No | No |
| 18034260 | PHARMACEUTICAL COMPOSITION AND METHOD FOR ENHANCING SOLUBILITY OF POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | April 2023 | November 2025 | Allow | 31 | 2 | 0 | No | No |
| 18135523 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | April 2023 | July 2024 | Allow | 15 | 1 | 0 | No | No |
| 18192491 | TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | March 2023 | July 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18186354 | BONE SUBSTITUTE COMPOSITION | March 2023 | December 2025 | Allow | 33 | 0 | 1 | No | No |
| 18019282 | MULTIFUNCTIONAL MICROSPHERE PREPARATION FOR CHEMOEMBOLIZATION THERAPY AND IMAGING OF TUMORS, AND PREPARATION METHOD THEREFOR | February 2023 | October 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 18096736 | USE OF SELF-ASSEMBLED ALKYLSILANE COATINGS FOR DRUG DELIVERY APPLICATIONS | January 2023 | March 2025 | Allow | 26 | 2 | 1 | Yes | No |
| 18153124 | PHARMACEUTICAL COMPOSITION CONTAINING CERIUM COMPOUND AS ACTIVE INGREDIENT | January 2023 | August 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 18013918 | SYSTEM FOR SHAPE MEMORY ALLOY ENABLED DRUG RELEASE | December 2022 | March 2026 | Allow | 39 | 2 | 0 | No | No |
| 18003180 | Hydrophilic Degradable Microsphere for Delivering Travoprost | December 2022 | December 2025 | Abandon | 36 | 0 | 1 | No | No |
| 18062191 | REVERSE ELECTRODIALYSIS DEVICE USING PRECIPITATION REACTION, AND DRUG INJECTION DEVICE USING SAME | December 2022 | November 2025 | Allow | 35 | 1 | 0 | No | No |
| 18058812 | COMPOSITIONS INCLUDING A VACANCY-ENGINEERED (VE)-ZnO NANOCOMPOSITE, METHODS OF MAKING THE COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS | November 2022 | October 2023 | Allow | 11 | 0 | 0 | No | No |
| 18053628 | EXPANDABLE HEMOSTATIC TABLETS COMPRISING OXIDIZED REGENERATED CELLULOSE | November 2022 | February 2026 | Allow | 39 | 1 | 1 | Yes | No |
| 18050311 | ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES AND METHODS OF USE | October 2022 | January 2025 | Abandon | 27 | 1 | 1 | No | No |
| 17960060 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | October 2022 | May 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17935172 | COLLAGEN-ARGINATE WOUND DRESSING MATERIAL AND METHOD FOR PRODUCING SAME | September 2022 | October 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17950499 | NOVEL CERIUM OXIDE NANOCOMPLEX AND A COMPOSITION FOR PREVENTING OR TREATING PERITONITIS COMPRISING THE SAME | September 2022 | February 2025 | Allow | 29 | 1 | 1 | No | No |
| 17912371 | DIETARY SUPPLEMENT FOR IMPROVING BRAIN PERFORMANCE | September 2022 | January 2026 | Abandon | 40 | 1 | 1 | No | No |
| 17908990 | DISSOLUTION-ENHANCED OLAPARIB COMPOSITION | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17899612 | CROSS-LINKED HYDROGEL MICRONEEDLE FOR TRANSDERMAL DRUG DELIVERY AND METHOD FOR PREPARING THE SAME | August 2022 | December 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17896525 | SPRAYABLE STIMULI-RESPONSIVE MICRO-HYDROGELS FOR ADHESION PREVENTION AND ENHANCED TISSUE HEALING | August 2022 | July 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17821905 | TESOFENSINE AND BETA BLOCKER COMBINATION FORMULATIONS | August 2022 | February 2024 | Allow | 18 | 1 | 0 | No | No |
| 17821794 | IRON OXIDE NANOPARTICLE FOR TARGETED CHEMO-IMMUNOTHERAPY | August 2022 | April 2025 | Allow | 32 | 2 | 1 | No | No |
| 17887821 | Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations | August 2022 | April 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17798547 | LITHIUM ION COMPOSITION AND APPLICATION THEREOF | August 2022 | October 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17882921 | THERAPEUTIC VIRAL MICROPARTICLES FOR PROMOTING STENT BIOFUNCTIONALITY AND WOUND HEALING IN VERTEBRATE INDIVIDUALS | August 2022 | February 2026 | Allow | 42 | 2 | 0 | No | No |
| 17815878 | NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEINS | July 2022 | March 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17855318 | ALLEVIATION OF ITCHING SENSATIONS USING CANNABINOID COMPOUNDS | June 2022 | June 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17808162 | BIODEGRADABLE POLYMERIC PARTICLES ENCAPSULATING AN ACTIVE AGENT, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | June 2022 | November 2025 | Abandon | 40 | 3 | 1 | No | No |
| 17836764 | PHYTOTHERAPY COMPOSITION ASSOCIATED WITH POLYVITAMIN AND MINERAL SUPPLEMENTS | June 2022 | April 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17830248 | Effects of Heparin on Topical Use of Plasters Containing a Non-Steroidal Anti-Inflammatory Drug | June 2022 | August 2025 | Abandon | 39 | 2 | 0 | No | Yes |
| 17750400 | OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHODS OF USE THEREOF, AND PREPARATION METHODS THEREOF | May 2022 | January 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17737399 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF | May 2022 | September 2025 | Allow | 41 | 1 | 0 | No | No |
| 17771276 | SWELLABLE ANTIMICROBIAL FIBRE | April 2022 | August 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17726121 | ORALLY DISSOLVING FILMS | April 2022 | February 2026 | Abandon | 45 | 2 | 0 | No | Yes |
| 17716189 | ANTI-DIABETIC STEROIDAL LACTONES OF WITHANIA COAGULANS FOR TREATMENT OF TYPE 2 DIABETES | April 2022 | August 2025 | Abandon | 40 | 3 | 1 | No | No |
| 17716892 | COMPOSITIONS FOR PROTECTION AGAINST PATHOGEN INFECTION AND METHOD THEREOF | April 2022 | December 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17715322 | STABLE HOT-MELT EXTRUDATE CONTAINING VALSARTAN AND SACUBITRIL | April 2022 | March 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17713856 | METHODS OF TREATING DOOSE SYNDROME USING FENFLURAMINE | April 2022 | June 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17713843 | SPREADABLE NUTRITIONAL SUPPLEMENT AND SPREADABLE MEDICINE | April 2022 | January 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17711910 | Biodegradable Implant Including Naltrexone | April 2022 | September 2025 | Allow | 42 | 3 | 1 | No | No |
| 17763386 | Antiperspirant/Deodorant Compositions | March 2022 | November 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17762856 | NEAR INFRARED BLOCKING AGENT AND NEAR INFRARED BLOCKING TOPICAL SKIN PREPARATION | March 2022 | July 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17699892 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | March 2022 | January 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17761760 | AMINO ACID-CONTAINING GRANULES | March 2022 | December 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17675842 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES | February 2022 | August 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17651201 | IRAK4 DEGRADERS AND USES THEREOF | February 2022 | August 2024 | Allow | 30 | 1 | 1 | No | No |
| 17650822 | INJECTABLE FORMULATION | February 2022 | March 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17586214 | METHODS, COMPOSITIONS, AND DELIVERY SYSTEMS FOR THERAPEUTIC SKIN TREATMENTS | January 2022 | April 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17628313 | BONE REGENERATIVE AGENT AND METHOD OF USING SAME | January 2022 | September 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17627741 | PHARMACEUTICAL COMPOSITION CONTAINING COMPLEXES OF ALLOFERON AND ZINC | January 2022 | April 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17570765 | COMPOSITION FOR REDUCING BODY FAT COMPRISING GREEN TEA EXTRACT CONTAINING GALLOCATECHIN GALLATE AS AN ACTIVE INGREDIENT AND MANUFACTURING METHOD THEREOF | January 2022 | May 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17554737 | COMPOSITION AND METHOD FOR PROTON PUMP INHIBITOR SUSPENSION | December 2021 | July 2023 | Allow | 19 | 1 | 0 | No | No |
| 17552333 | PROCESS FOR PREPARING ARIPIPRAZOLE ORAL SOLUBLE FILM | December 2021 | May 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17546489 | HYDROGEL COMPOSITIONS COMPRISING ENCAPSULATED CELLS AND METHODS OF USE THEREOF | December 2021 | September 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17538333 | MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | November 2021 | March 2024 | Abandon | 27 | 2 | 0 | No | No |
| 17535815 | PHARMACEUTICAL COMPOSITION COMPRISING MARMELO EXTRACT FOR PREVENTING OR TREATING OBESITY | November 2021 | April 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17519583 | PEPTIDE COMPOSITION FROM EARLY HARVESTED RICE AND METHODS FOR SLIMMING OR PROMOTING GROWTH OF PROBIOTICS USING THE SAME | November 2021 | November 2023 | Allow | 24 | 0 | 1 | Yes | No |
| 17608215 | DOSAGE FORMS FOR PREVENTING DRUG-FACILITATED ASSAULT | November 2021 | March 2026 | Abandon | 52 | 4 | 1 | Yes | No |
| 17607965 | INHALABLE GASEOUS MIXTURE FOR TREATING CHRONIC PAIN IN PATENTS RECEIVING DRUGS FROM MULTIPLE THERAPEUTIC CLASSES | November 2021 | January 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17514133 | NICKEL CHELATION THERAPY | October 2021 | October 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17511122 | Embolization Device Constructed From Expansile Polymer | October 2021 | December 2024 | Abandon | 38 | 4 | 0 | Yes | No |
| 17504861 | MITIGATING ADVERSE EFFECTS OF SUNLIGHT WITH INGREDIENTS OBTAINED FROM LIVING PLANTS | October 2021 | May 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17439581 | EFFICIENT SUNSCREEN COMPOSITIONS WITH DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE AND ORGANIC PARTICULATE UV FILTER | September 2021 | October 2025 | Abandon | 49 | 3 | 0 | No | No |
| 17473123 | SURGICAL SYSTEM AND METHODS OF USE | September 2021 | November 2025 | Abandon | 51 | 4 | 0 | No | Yes |
| 17461867 | DEMINERALIZED BONE MATRIX HAVING IMPROVED HANDLING CHARACTERISTICS | August 2021 | June 2023 | Allow | 21 | 1 | 0 | Yes | No |
| 17446249 | RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | August 2021 | April 2023 | Allow | 20 | 1 | 0 | No | No |
| 17445918 | EFFERVESCENT COMPOSITION AND METHOD OF MAKING IT | August 2021 | October 2022 | Allow | 13 | 1 | 1 | Yes | No |
| 17409301 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | August 2021 | December 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17409313 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | August 2021 | November 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17432999 | AN ANTIPERSPIRANT COMPOSITION COMPRISING REACTIVE SALTS | August 2021 | October 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17432492 | USE OF SALIDROSIDE DERIVATIVE IN EXTERNAL PREPARATION FOR SKIN WHITENING | August 2021 | October 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17406934 | Anti-Microbial Medical Materials and Devices | August 2021 | July 2025 | Allow | 47 | 4 | 1 | No | No |
| 17400407 | ORAL CARE COMPOSITIONS COMPRISING BENZOCAINE AND MUCOADHESIVE THIN FILMS FORMED THEREFROM | August 2021 | March 2023 | Allow | 19 | 0 | 1 | No | No |
| 17310400 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF LYSOSOMAL STORAGE DISORDERS | July 2021 | November 2024 | Allow | 39 | 1 | 0 | No | No |
| 17426629 | HYDROGEL HYBRID MATERIAL, METHOD OF ITS PREPARATION AND APPLICATION | July 2021 | July 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17386426 | Methods and Devices for Conduit Occlusion | July 2021 | May 2023 | Allow | 22 | 2 | 0 | No | No |
| 17380843 | THYROID HORMONE ORAL DOSAGE FORMS AND METHODS OF USING THE SAME | July 2021 | March 2023 | Allow | 20 | 1 | 0 | No | No |
| 17375596 | THYROID HORMONE ORAL DOSAGE FORMS AND METHODS OF USING THE SAME | July 2021 | April 2023 | Allow | 21 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CRAIGO, WILLIAM A.
With a 15.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CRAIGO, WILLIAM A works in Art Unit 1615 and has examined 760 patent applications in our dataset. With an allowance rate of 48.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner CRAIGO, WILLIAM A's allowance rate of 48.0% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CRAIGO, WILLIAM A receive 2.46 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CRAIGO, WILLIAM A is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +43.4% benefit to allowance rate for applications examined by CRAIGO, WILLIAM A. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.2% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 35.0% of cases where such amendments are filed. This entry rate is in the 52% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 28.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 30% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 70.5% of appeals filed. This is in the 57% percentile among all examiners. Of these withdrawals, 61.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 52.0% are granted (fully or in part). This grant rate is in the 51% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.1% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 56% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.